Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors

  • Body, Amy (Primary Chief Investigator (PCI))
  • Day, Daphne (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

ERM Reference Number: 96955
Monash Health Local Reference: RES-23-0000-213A
StatusActive
Effective start/end date21/07/23 → 20/07/28

Clinical Trial Phase

  • Phase I